However, mirabegron is shown to accelerate aortic atherosclerotic plaque development and instability in high-fat diet apolipoprotein E (ApoE) knockout mice (a pre-clinical model of atherosclerosis), which were administered a clinical dose orally (0.8mg/kg in C57BL/6 mice, equivalent to 50 mg in humans), likely due to increased circulating LDL and VLDL cholesterol remnants from adipose browning. Here, APOE is linked to atherosclerosis.